Human Bone Marrow-Derived Mesenchymal Stem Cells

Nasef, Aisha; Fouillard, L; El-Taguri, A; Lopez, M.

doi:10.4176/070705

Cited by 7 publications

(2 citation statements)

References 154 publications

(188 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BM-MSCs have been investigated and used for tissue regeneration and cell-based therapies (Alhadlaq & Mao, 2004;Samsonraj et al, 2017). However, the quantity of MSCs found in the BM is very low and ranges from 1/10,000 to 1/100,000 of cells in the BM tissue (Nasef, Fouillard, El-Taguri, & Lopez, 2007). BM-MSCs have the potential risk of graft-vs-host disease (GvHD; Amorin et al, 2014).…”

mentioning

confidence: 99%

Mesenchymal stem cells: Cell therapy and regeneration potential

Brown

McKee

Bakshi

et al. 2019

J Tissue Eng Regen Med

428

310

View full text Add to dashboard Cite

Rapid advances in the isolation of multipotent progenitor cells, routinely called mesenchymal stromal/stem cells (MSCs), from various human tissues and organs have provided impetus to the field of cell therapy and regenerative medicine. The most widely studied sources of MSCs include bone marrow, adipose, muscle, peripheral blood, umbilical cord, placenta, fetal tissue, and amniotic fluid. According to the standard definition of MSCs, these clonal cells adhere to plastic, express cluster of differentiation (CD) markers such as CD73, CD90, and CD105 markers, and can differentiate into adipogenic, chondrogenic, and osteogenic lineages in vitro. However, isolated MSCs have been reported to vary in their potency and self‐renewal potential. As a result, the MSCs used for clinical applications often lead to variable or even conflicting results. The lack of uniform characterization methods both in vitro and in vivo also contributes to this confusion. Therefore, the name “MSCs” itself has been increasingly questioned lately. As the use of MSCs is expanding rapidly, there is an increasing need to understand the potential sources and specific potencies of MSCs. This review discusses and compares the characteristics of MSCs and suggests that the variations in their distinctive features are dependent on the source and method of isolation as well as epigenetic changes during maintenance and growth. We also discuss the potential opportunities and challenges of MSC research with the hope to stimulate their use for therapeutic and regenerative medicine.

show abstract

mentioning

confidence: 99%

Mesenchymal stem cells: Cell therapy and regeneration potential

Brown

McKee

Bakshi

et al. 2019

J Tissue Eng Regen Med

428

310

View full text Add to dashboard Cite

show abstract

“…The limitations of the MSC expansion methods are the excessive number of passages required for a sufficient cell number (50 passages are necessary for the 500-fold increase). 28 A high number of in vitro passages introduce genetic instability such as DNA damage accumulation and transformation concerns. 29 Accordingly, long-term replated MSCs (passage 25 has been considered critical) show lower proliferative and differentiation potential along with disrupted homing and cytokine/chemokine release capacity.…”

Section: Mscs Physiology and Therapeutical Features At A Glancementioning

confidence: 99%

Steering the multipotent mesenchymal cells towards an anti-inflammatory and osteogenic bias via photobiomodulation therapy: How to kill two birds with one stone

et al. 2022

View full text Add to dashboard Cite

The bone marrow-derived multipotent mesenchymal cells (MSCs) have captured scientific interest due to their multi-purpose features and clinical applications. The operational dimension of MSCs is not limited to the bone marrow reservoir, which exerts bone-building and niche anabolic tasks; they also meet the needs of quenching inflammation and restoring inflamed tissues. Thus, the range of MSC activities extends to conditions such as neurodegenerative diseases, immune disorders and various forms of osteopenia. Steering these cells towards becoming an effective therapeutic tool has become mandatory. Many laboratories have employed distinct strategies to improve the plasticity and secretome of MSCs. We aimed to present how photobiomodulation therapy (PBM-t) can manipulate MSCs to render them an extraordinary anti-inflammatory and osteogenic instrument. Moreover, we discuss the outcomes of different PBM-t protocols on MSCs, concluding with some perplexities and complexities of PBM-t in vivo but encouraging and feasible in vitro solutions.

show abstract

A comparative study of PKH67, DiI, and BrdU labeling techniques for tracing rat mesenchymal stem cells

Nagyova

Slovinská

Blasko

et al. 2014

In Vitro Cell.Dev.Biol.-Animal

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have generated a great deal of promise as a potential source of cells for cell-based therapies. Various labeling techniques have been developed to trace MSC survival, migration, and behavior in vitro or in vivo. In the present study, we labeled MSCs derived from rat bone marrow (rMSCs) with florescent membrane dyes PKH67 and DiI, and with nuclear labeling using 5 μM BrdU and 10 μM BrdU. The cells were then cultured for 6 d or passaged (1-3 passages). The viability of rMSCs, efficacy of fluorescent expression, and transfer of the dyes were assessed. Intense fluorescence in rMSCs was found immediately after membrane labeling (99.3 ± 1.6% PKH67+ and 98.4 ± 1.7% DiI+) or after 2 d when tracing of nuclei was applied (91.2 ± 4.6% 10 μM BrdU+ and 77.6 ± 4.6% 5 μM BrdU+), which remained high for 6 d. Viability of labeled cells was 91 ± 3.8% PKH67+, 90 ± 1.5% DiI+, 91 ± 0.8% 5 μM BrdU+, and 76.9 ± 0.9% 10 μM BrdU+. The number of labeled rMSCs gradually decreased during the passages, with almost no BrdU+ nuclei left at final passage 3. Direct cocultures of labeled rMSCs (PKH67+ or DiI+) with unlabeled rMSCs revealed almost no dye transfer from donor to unlabeled recipient cells. Our results confirm that labeling of rMSCs with PKH67 or DiI represents a non-toxic, highly stable, and efficient method suitable for steady tracing of cells, while BrdU tracing is more appropriate for temporary labeling due to decreasing signal over time.

show abstract

Human Bone Marrow-Derived Mesenchymal Stem Cells

Cited by 7 publications

References 154 publications

Mesenchymal stem cells: Cell therapy and regeneration potential

Mesenchymal stem cells: Cell therapy and regeneration potential

Steering the multipotent mesenchymal cells towards an anti-inflammatory and osteogenic bias via photobiomodulation therapy: How to kill two birds with one stone

A comparative study of PKH67, DiI, and BrdU labeling techniques for tracing rat mesenchymal stem cells

Contact Info

Product

Resources

About